Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06744920 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
A Phase 3 study of Generalized Myasthenia Gravis, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 180
- Enrollment target
- 20
- Study locations
NCT06744920 is a Phase 3 study of Generalized Myasthenia Gravis that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 180 participants, above the 124-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (45% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT06744920, a Phase 3 study of Generalized Myasthenia Gravis, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care (SOC) treatment.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Remibrutinib (Blinded)
- DRUG Remibrutinib (Open Label)
Study Locations (20)
Florida
- SFM Clinical Research LLC - Boca Raton
- Homestead Assoc In Research Inc - Homestead
- AdventHealth - Orlando
- Neurological Services of Orlando PA - Orlando
California
- Fullerton Neuro and Headache Ctr - Fullerton
- University Of Southern California - Los Angeles
- Univ Cali Irvine ALS Neuromuscular - Orange
Arizona
- Neuromuscular Research Center - Phoenix
- Honor Health Research Institute - Scottsdale
Texas
- Houston Methodist Hospital - Houston
- UT Health Science Center - Houston
Maryland
- Mid Atlantic Epilepsy and Sleep Ctr - Bethesda
Michigan
- Michigan State University-Department of Neurology - East Lansing
New York
- Dent Neurological Institute - Buffalo
Ohio
- Univ of Cincinnati Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2025-02-07 |
| Est. Completion | 2033-02-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06744920
The ClinicalTrials.gov registry entry for NCT06744920 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 124-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (45% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Generalized Myasthenia Gravis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06744920 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06744920 about?
NCT06744920 is a clinical study titled "A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis". A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care (SOC) treatment.
What is the current status of trial NCT06744920?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 180 participants. The study started on 2025-02-07. Estimated completion is 2033-02-26.
What conditions does trial NCT06744920 study?
This clinical trial studies the following conditions: Generalized Myasthenia Gravis.
What interventions are being tested in trial NCT06744920?
The interventions under investigation include: Placebo (OTHER), Remibrutinib (Blinded) (DRUG), Remibrutinib (Open Label) (DRUG).
Who is sponsoring clinical trial NCT06744920?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06744920 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
RECRUITING · Phase 3
-
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
RECRUITING · Phase 3
-
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.